Thermo Fisher Scientific (TMO) Stock Price, News & Analysis

Company Overview

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies. Customers span academic and government research institutions, pharmaceutical and biotech firms, hospitals and clinical labs, and industrial and environmental testing organizations. The company’s product portfolio ranges from benchtop tools and reagents to high-end mass spectrometers, genomic sequencing platforms, and bioprocessing systems used in drug development and manufacturing.

Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific was formed through the 2006 combination of Thermo Electron and Fisher Scientific and has since grown its global footprint through organic investment and strategic acquisitions, including notable transactions that expanded its molecular and bioproduction capabilities. The company maintains operations and sales across North America, Europe, Asia-Pacific and other international markets, supporting a global customer base.

Thermo Fisher is led by an executive team responsible for overseeing its diverse portfolio and global operations; the company emphasizes innovation, regulatory compliance and customer services as core components of its strategy to serve life science research, clinical diagnostics and industrial markets.

Key Stats

• Today's Range: $437.32 to $444.95
• 50-Day Range: $438.16 to $531.69
• 52-Week Range: $385.46 to $643.99
• Volume: 2.04 million shs
• Average Volume: 2.47 million shs
• Market Capitalization: $162.83 billion
• P/E Ratio: 24.09
• Dividend Yield: 0.43%
• Price Target: $616.10
• Consensus Rating: Moderate Buy

Thermo Fisher Scientific Stock Analysis - MarketRank™

Thermo Fisher Scientific scored higher than 95% of companies evaluated by MarketBeat, and ranked 25th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Thermo Fisher Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 2 strong buy ratings, 18 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Thermo Fisher Scientific has a consensus price target of $616.10, representing about 40.6% upside from its current price of $438.16.

Amount of Analyst Coverage

Thermo Fisher Scientific has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 9.77%

Earnings Growth

Earnings for Thermo Fisher Scientific are expected to grow by 9.77% in the coming year, from $24.86 to $27.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Thermo Fisher Scientific is 24.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Thermo Fisher Scientific is 24.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.38.

Price to Earnings Growth Ratio

Thermo Fisher Scientific has a PEG Ratio of 1.98. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Thermo Fisher Scientific has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.31% of the float of Thermo Fisher Scientific has been sold short.

Short Interest Ratio / Days to Cover

Thermo Fisher Scientific has a short interest ratio ("days to cover") of 2.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Thermo Fisher Scientific has recently increased by 7.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Thermo Fisher Scientific has a dividend yield of 0.42%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Thermo Fisher Scientific has been increasing its dividend for 8 years.

Dividend Coverage

The dividend payout ratio of Thermo Fisher Scientific is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Thermo Fisher Scientific will have a dividend payout ratio of 6.89% next year. This indicates that Thermo Fisher Scientific will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.25

News Sentiment

Thermo Fisher Scientific has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Thermo Fisher Scientific this week, compared to 13 articles on an average week.

Search Interest

54 people have searched for TMO on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

MarketBeat Follows

Only 12 people have added Thermo Fisher Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Thermo Fisher Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,747,064.00 in company stock.

Percentage Held by Insiders

0.33% of the stock of Thermo Fisher Scientific is held by insiders.

Percentage Held by Institutions

89.23% of the stock of Thermo Fisher Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 4/15 Dividend: 3/13/2026
• Ex-Dividend for 4/15 Dividend: 3/13/2026
• Dividend Payable: 4/15/2026
• Last Earnings: 4/23/2026
• Today: 5/16/2026
• Investor Day 2026: 5/20/2026
• AGM 2026: 5/20/2026
• Next Earnings (Estimated): 7/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:TMO
• CIK: 97745
• Web: www.thermofisher.com
• Phone: (781) 622-1000
• Fax: 781-622-1207
• Employees: 125,000
• Year Founded: 1956

Price Target and Rating

• Average Price Target for Thermo Fisher Scientific: $616.10
• High Price Target: $750.00
• Low Price Target: $490.00
• Potential Upside/Downside: +40.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.96
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $18.19
• Trailing P/E Ratio: 24.09
• Forward P/E Ratio: 17.63
• P/E Growth: 1.98
• Net Income: $6.70 billion
• Net Margins: 15.15%
• Pretax Margin: 16.42%
• Return on Equity: 16.86%
• Return on Assets: 8.15%

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 1.53
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $45.20 billion
• Price / Sales: 3.60
• Cash Flow: $29.73 per share
• Price / Cash Flow: 14.74
• Book Value: $139.77 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 371,621,000
• Free Float: 370,395,000
• Market Cap: $162.83 billion
• Optionable: Optionable
• Beta: 0.88